GAMMA Investing LLC Has $237,000 Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

GAMMA Investing LLC grew its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 7,690.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,415 shares of the company’s stock after purchasing an additional 2,384 shares during the period. GAMMA Investing LLC’s holdings in Keros Therapeutics were worth $237,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. AlphaQuest LLC increased its position in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after purchasing an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC increased its position in Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Keros Therapeutics in the 4th quarter worth about $90,000. CANADA LIFE ASSURANCE Co increased its position in Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock worth $116,000 after purchasing an additional 4,976 shares during the last quarter. Finally, ProShare Advisors LLC increased its position in Keros Therapeutics by 35.5% in the 4th quarter. ProShare Advisors LLC now owns 10,549 shares of the company’s stock worth $167,000 after purchasing an additional 2,764 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Stock Down 0.4%

Shares of NASDAQ:KROS opened at $13.49 on Friday. The business has a 50 day moving average price of $14.07 and a 200 day moving average price of $14.89. Keros Therapeutics, Inc. has a twelve month low of $9.12 and a twelve month high of $72.37. The company has a market cap of $547.96 million, a price-to-earnings ratio of -74.94 and a beta of 1.31.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $3.63. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. The firm had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. During the same quarter in the prior year, the company earned ($1.21) EPS. Analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on KROS shares. Truist Financial dropped their target price on Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, April 9th. HC Wainwright lowered their price objective on Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Wedbush reissued a “neutral” rating and set a $15.00 price objective on shares of Keros Therapeutics in a report on Friday, May 30th. Wells Fargo & Company lowered their price objective on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a report on Thursday, February 27th. Finally, Bank of America lowered Keros Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.56.

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of Keros Therapeutics stock in a transaction on Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the transaction, the insider now owns 4,392,737 shares of the company’s stock, valued at $44,498,425.81. The trade was a 27.01% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 20.60% of the company’s stock.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.